(IN BRIEF) The European Commission has approved Theralugand®, Eckert & Ziegler’s high-purity Lutetium-177 chloride, for routine clinical use across the European Economic Area. This approval allows its application in targeted cancer therapies, such as for neuroendocrine tumors and metastatic prostate … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Cancer Therapies, Dr. Harald Hasselmann, Eckert & Ziegler, EU, Healthcare, safety, Theralugand®, wellness
(IN BRIEF) Sanofi and Orano Med have partnered to accelerate the development of next-generation radioligand therapies (RLTs) for rare cancers. By combining their expertise, they aim to advance treatments using lead-212 (212Pb) alpha-emitting isotopes, which target and destroy cancer cells … Read the full press release
Posted in Business, Environment, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Cancer Therapies, Nicolas Maes, Orano Med, partnership, Paul Hudson, radioligand therapies (RLTs), rare cancers, safety, Sanofi, sustainability, USA
(IN BRIEF) Belgium-based PanTera has raised €134 million in a Series A funding round led by EQT Life Sciences to accelerate the large-scale production of actinium-225 (225Ac), a crucial isotope for Targeted Alpha Therapy (TAT) used in cancer treatment. The … Read the full press release
Posted in Belgium, Business, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Science, Sweden, Technology
Tagged Actinium-225, Belgium, Cancer Therapies, EQT, PanTera, partnership, shortage, sustainabilty
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
